Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
2022 · New England Journal of Medicine · 1,001 citations
https://doi.org/10.1056/nejmoa2206443
J
James Rucker
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
214
Papers
7.8K
Citations
37
h-index
84
i10-index
James Rucker is an academic researcher from CURE International UK. The author has contributed to research in topics: Psychedelics and Drug Studies & Cannabis and Cannabinoid Research & Chemical synthesis and alkaloids. The author has an h-index of 37, co-authored 182 publications.
ORCID: 0000-0003-4647-8088Papers by this author
worksPsilocybin with psychological support for treatment-resistant depression: six-month follow-up
2017 · Psychopharmacology · 935 citations
https://doi.org/10.1007/s00213-017-4771-x
Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis
2022 · Journal of Affective Disorders · 129 citations
https://doi.org/10.1016/j.jad.2022.09.168
Depressive disorder moderates the effect of the FTO gene on body mass index
2011 · Molecular Psychiatry · 85 citations
https://doi.org/10.1038/mp.2011.45
Expectancy in placebo-controlled trials of psychedelics: if so, so what?
2022 · Psychopharmacology · 79 citations
https://doi.org/10.1007/s00213-022-06221-6
Dose response of the 16p11.2 distal copy number variant on intracranial volume and basal ganglia
2018 · Molecular Psychiatry · 74 citations
https://doi.org/10.1038/s41380-018-0118-1
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat